NYSE:ACBAurora Cannabis Stock Price, Forecast & News

Aurora Cannabis' stock was trading at $10.3044 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACB shares have increased by 38.1% and is now trading at $14.23. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurora Cannabis in the last year. There are currently 5 sell ratings, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aurora Cannabis.

Aurora Cannabis is scheduled to release its next quarterly earnings announcement on Wednesday, September 9th 2020. View our earnings forecast for Aurora Cannabis.

Aurora Cannabis Inc (NYSE:ACB) released its earnings results on Thursday, November, 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.48. The company had revenue of $57.02 million for the quarter, compared to analysts' expectations of $72.82 million. Aurora Cannabis had a negative net margin of 442.62% and a negative return on equity of 8.55%. View Aurora Cannabis' earnings history.

Aurora Cannabis's stock reverse split before market open on Monday, May 11th 2020. The 1-12 reverse split was announced on Friday, May 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 8th 2020. An investor that had 100 shares of Aurora Cannabis stock prior to the reverse split would have 8 shares after the split.

17 analysts have issued 12-month price objectives for Aurora Cannabis' shares. Their forecasts range from $10.00 to $108.00. On average, they anticipate Aurora Cannabis' share price to reach $27.93 in the next year. This suggests a possible upside of 96.3% from the stock's current price. View analysts' price targets for Aurora Cannabis.

News headlines about ACB stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aurora Cannabis earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutAurora Cannabis.

Aurora Cannabis saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 217,440,000 shares, an increase of 13.1% from the April 15th total of 192,210,000 shares. Based on an average trading volume of 31,400,000 shares, the short-interest ratio is currently 6.9 days. Approximately 16.7% of the company's stock are sold short. View Aurora Cannabis' Current Options Chain.

Some companies that are related to Aurora Cannabis include STADA Arzneimittel (STDAF), Cronos Group (CRON), USANA Health Sciences (USNA), Tilray (TLRY), Aphria (APHA), Canopy Rivers (RIV), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU) and FitLife Brands (FTLF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurora Cannabis investors own include Canopy Growth (CGC), Cronos Group (CRON), Aphria (APHA), HEXO (HEXO), NVIDIA (NVDA), Tilray (TLRY), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU) and General Electric (GE).

Aurora Cannabis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ACB."

Aurora Cannabis' stock is owned by a variety of retail and institutional investors. Top institutional investors include ETF Managers Group LLC (26.85%), Swiss National Bank (0.35%), Public Sector Pension Investment Board (3.45%), Morgan Stanley (3.29%), Morgan Stanley (3.29%) and JPMorgan Chase & Co. (0.24%).

ACB stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Janus Henderson Group PLC, CIBC World Markets Inc., Cambridge Investment Research Advisors Inc., CIBC Asset Management Inc, AdvisorShares Investments LLC, Sigma Planning Corp, and Raymond James Financial Services Advisors Inc..

ACB stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Swiss National Bank, Voloridge Investment Management LLC, SG Americas Securities LLC, Public Sector Pension Investment Board, Geode Capital Management LLC, Bank of New York Mellon Corp, and Morgan Stanley.

Shares of ACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACB stock can currently be purchased for approximately $14.23.

Aurora Cannabis has a market capitalization of $1.45 billion and generates $215.10 million in revenue each year. The company earns $-219,670,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Aurora Cannabis employs 2,779 workers across the globe.

The official website for Aurora Cannabis is auroramj.com.

Aurora Cannabis' mailing address is 10355 JASPER AVENUE SUITE 500, EDMONTON A0, T5J 1Y6. The company can be reached via phone at 1-855-279-4652 or via email at [email protected]